Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Praulent

- PMLiVE

Novartis says Indian Glivec verdict “discourages innovation”

Country's Supreme Court denies the cancer drug patent protection

Novartis building

Pharma waits for Glivec patent verdict in India

Intellectual property decision could have far-reaching consequences for industry

- PMLiVE

Interview: Pierre Chancel, Sanofi Diabetes

The head of Sanofi Diabetes shares the company’s strategy to keep pace with the race against this ‘hidden disease’

- PMLiVE

NICE gives final ‘yes’ to cystic fibrosis drugs from Novartis and Forest

NICE backs Tobi Podhaler and Colobreathe for NHS use

Sanofi reception

Sanofi to act as contract manufacturer for Transgene

French biopharma partners with its big pharma compatriot on long-term deal

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

Sanofi reception

Follow-up data suggests long-term benefit of Sanofi’s Lemtrada in MS

Drug has a durable effect on relapse rates and disability progression

- PMLiVE

Amgen says viral melanoma therapy clears phase III trial

OncoVex demonstrates durable response in skin cancer patients

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

Tetra wins Meningitis UK account

Public affairs agency will promote NHS adoption of vaccine 

- PMLiVE

Merck Serono signs diabetes partnership with BMS in China

Will co-promote Glucophage (metformin) formulations

- PMLiVE

Bayer’s Eylea data not suitable, says IQWiG

German HTA body unhappy with Lucentis comparison data and turns down Bayer-Regeneron wet AMD drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links